With the 2017 release of the Biomanufacturing Technology Roadmap published by BioPhorum Operations Group, 1 our industry projected a clear vision for the future of monoclonal antibody (mAb) production ...

Process intensification (PI) enhances the efficiency, flexibility, and sustainability of complex molecule manufacturing by reducing costs and increasing throughput. That is why the monoclonal antibody ...

The long journey from cell culture to a purified monoclonal antibody (mAb) involves many sample processing steps, with clarification and filtration playing significant roles. However, clogs, complex ...

I-Mab acquires Bridge Health, gaining upstream rights to CLDN18.2 antibody, reducing milestone payments for givastomig and eliminating royalties. I-Mab has announced its acquisition of Bridge Health ...